CNR1 and depressive symptom measurement: Taken together, the data suggest that enhancing endocannabinoid signaling may serve as an antidepressant; CB1r blockade produces depression; and chronic direct activation of CB1r may produce region-dependent CB1r desensitization and down-regulation that is associated with depression [21].